Table 5.
Time to initiation of open-triple therapy at 12 months (post-index date)
| Description | Patients initiating on LAMA | Patients initiating on ICS/LABA | P-value |
|---|---|---|---|
| Observation period, days, mean (SD) | |||
| All patientsa | 321 (93) | 320 (92) | 0.894 |
| Patients with PFT information availableb | 328 (85) | 320 (91) | 0.147 |
| Patients with asthmac | 325 (90) | 322 (87) | 0.629 |
| Patients without asthmad | 319 (94) | 319 (94) | 0.958 |
| Patients initiating open-triple therapy, n (%) | |||
| All patientsa | 226 (15.4) | 174 (7.7) | <0.001 |
| Patients with PFT information availableb | 75 (20.2) | 57 (8.4) | <0.001 |
| Patients with asthmac | 70 (21.6) | 53 (6.8) | <0.001 |
| Patients without asthmad | 156 (13.7) | 121 (8.2) | <0.001 |
| Time to open-triple therapy, days, mean (SD) | |||
| All patientsa | 79.8 (89.0) | 122.9 (105.4) | <0.001 |
| Patients with PFT information availableb | 105.9 (101.3) | 131.5 (109.4) | 0.166 |
| Patients with asthmac | 87.9 (99.1) | 131.6 (115.5) | 0.026 |
| Patients without asthmad | 76.2 (84.2) | 119.1 (100.9) | <0.001 |
Notes:
a
Patients initiating on LAMA: N=1,463; patients initiating on ICS/LABA: N=2,259;
b
patients initiating on LAMA: N=371; patients initiating on ICS/LABA: N=679;
c
patients initiating on LAMA: N=324; patients initiating on ICS/LABA: N=775;
d
patients initiating on LAMA: N=1,139; patients initiating on ICS/LABA: N=1,484.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; PFT, pulmonary-function testing; SD, standard deviation.